Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Daiichi Sankyo's Ifinatamab Deruxtecan?
Ifinatamab Deruxtecan is a monoclonal antibody conjugated commercialized by Daiichi Sankyo, with a leading Phase III program in Small-Cell Lung...